|
業務類別
|
Biotechnology |
|
業務概覽
|
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients withB cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies,or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases. |
| 公司地址
| 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104 |
| 電話號碼
| +1 267 759-3100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cabalettabio.com |
| 員工數量
| 164 |
| Dr. Steven Nichtberger,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 646.33K |
13/05/2025 |
| Dr. Gwendolyn K. Binder, PhD |
President, Science and Technology |
美元 496.92K |
13/05/2025 |
| Mr. Anup Marda, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
13/05/2025 |
| Mr. David J. Chang, M.D.,M.P.H. |
Chief Medical Officer |
美元 496.83K |
13/05/2025 |
| Mr. Michael Gerard, J.D. |
General Counsel and Secretary |
-- |
13/05/2025 |
| Mr. Arun Das, M.D. |
Chief Business Officer |
-- |
13/05/2025 |
|
|
| Mr. Richard C. Henriques, M.B.A. |
Independent Director |
13/05/2025 |
| Dr. Steven Nichtberger,M.D. |
Chairman of the Board, President and Chief Executive Officer |
13/05/2025 |
| Ms. Shawn Cline Tomasello, M.B.A. |
Independent Director |
13/05/2025 |
| Dr. Catherine Bollard, M.D.,MB.Ch.B. |
Independent Director |
13/05/2025 |
| Mr. Mark Simon, M.B.A. |
Independent Director |
13/05/2025 |
| Dr. Scott C. Brun, M.D. |
Independent Director |
13/05/2025 |
|
|
|
|
